In re Effexor XR Antitrust Litigation

Brief of the Federal Trade Commission urging the Third Circuit to reject the district court’s holding that an alleged reverse-payment settlement agreement between a brand-name drug company and a generic drug company was shielded from antitrust scrutiny because they submitted it in advance to the FTC and the FTC declined to file an objection with the court hearing the patent case.